Mediforum
Mediforum is a South Korea–based bio‑medical company focused on developing natural‑product therapeutics, molecular diagnostic kits, genetic tests and nutraceuticals. The company conducts preclinical and clinical development of candidate drugs (including Alzheimer’s and non‑narcotic analgesic candidates), develops and supplies PCR‑based diagnostic assays for HPV and STDs, provides genetic testing services (including ApoE genotyping), and operates with multiple international certifications and manufacturing/quality approvals.
Industries
Nr. of Employees
small (1-50)
Products
PM‑012 (natural‑substance combination candidate for dementia)
A multi‑component natural‑substance drug candidate aimed at improving brain metabolism and neuronal function; progressed through Phase IIa/IIb clinical trials and preparing for Phase III.
MF‑018 (non‑narcotic analgesic candidate)
A non‑opioid analgesic candidate developed from natural substances intended to treat chemotherapy‑induced peripheral neuropathy and other pain conditions; undergoing Phase II clinical trials.
HPV and STD real‑time PCR kit family
A portfolio of real‑time PCR diagnostic kits for HPV detection and genotyping and for screening/detection of common STDs.
ApoE genotyping test
Genetic test for ApoE genotype used in early dementia risk assessment.
Heat‑treated synbiotic probiotic formulations (functional foods)
Functional food / probiotic products developed and marketed for gut health, weight management and immunity, presented as heat‑stable synbiotic formulations.
PM‑012 (natural‑substance combination candidate for dementia)
A multi‑component natural‑substance drug candidate aimed at improving brain metabolism and neuronal function; progressed through Phase IIa/IIb clinical trials and preparing for Phase III.
MF‑018 (non‑narcotic analgesic candidate)
A non‑opioid analgesic candidate developed from natural substances intended to treat chemotherapy‑induced peripheral neuropathy and other pain conditions; undergoing Phase II clinical trials.
HPV and STD real‑time PCR kit family
A portfolio of real‑time PCR diagnostic kits for HPV detection and genotyping and for screening/detection of common STDs.
ApoE genotyping test
Genetic test for ApoE genotype used in early dementia risk assessment.
Heat‑treated synbiotic probiotic formulations (functional foods)
Functional food / probiotic products developed and marketed for gut health, weight management and immunity, presented as heat‑stable synbiotic formulations.
Services
Collaborative clinical trial services and project management through MOUs and service contracts with CROs to execute Phase II/III studies.
Development and supply of PCR‑based diagnostic kits for HPV screening, HPV genotyping, and STD detection.
Provision of genetic tests including ApoE genotyping for dementia risk and tests for product/ingredient authenticity.
Collaborative clinical trial services and project management through MOUs and service contracts with CROs to execute Phase II/III studies.
Development and supply of PCR‑based diagnostic kits for HPV screening, HPV genotyping, and STD detection.
Provision of genetic tests including ApoE genotyping for dementia risk and tests for product/ingredient authenticity.
Expertise Areas
- Natural‑product drug discovery
- Clinical trial management (Phase II/III)
- Molecular diagnostics (real‑time PCR)
- Genetic testing and genotyping
Key Technologies
- Real‑time PCR
- Genotyping assays
- ApoE genotyping
- PCR‑based HPV and STD diagnostics
News & Updates
Announcement of MOU with a SPAC sponsor to pursue a NASDAQ listing via SPAC merger and related MOU ceremony (reported Nov 25–26, 2022).
Announcement of service contracts with SPAC/IPOs specialists to pursue NASDAQ SPAC merger and listing (service contract announced Aug 31, 2022).
MOU signed with a contract research organization to jointly conduct clinical Phase II development of the non‑narcotic analgesic candidate.
Press release distributed via AP/EIN describing planned NASDAQ listing via SPAC and clinical development status of lead candidates.
The MF‑018 candidate was selected among the 2020 'National R&D Top 100' outcomes.
ISO 13485:2016 quality management system certification recorded in company history.
Announcement of MOU with a SPAC sponsor to pursue a NASDAQ listing via SPAC merger and related MOU ceremony (reported Nov 25–26, 2022).
Announcement of service contracts with SPAC/IPOs specialists to pursue NASDAQ SPAC merger and listing (service contract announced Aug 31, 2022).
MOU signed with a contract research organization to jointly conduct clinical Phase II development of the non‑narcotic analgesic candidate.
Press release distributed via AP/EIN describing planned NASDAQ listing via SPAC and clinical development status of lead candidates.
The MF‑018 candidate was selected among the 2020 'National R&D Top 100' outcomes.
ISO 13485:2016 quality management system certification recorded in company history.